Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy

Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy

Background There is great interest in finding ways to identify patients who will develop toxicity to cancer therapies. This has become especially pressing in the era of immune therapy, where toxicity can be long-lasting and life-altering, and primarily comes in the form of immune-related adverse eff...

Full description

Saved in:
Bibliographic Details
Main Authors: Santosh Kesari, Jose Carrillo, Alexandra Drakaki, Joanne Weidhaas, Mark Scholz, Nicholas Marco, Aaron W Scheffler, Anusha Kalbasi, Kirk Wilenius, Emily Rietdorf, Jaya Gill, Mara Heilig, Caroline Desler, Robert K Chin, Tania Kaprealian, Susan McCloskey, Ann Raldow, Naga P Raja, Donatello Telesca
Format: Article
Language:English
Published: BMJ Publishing Group 2022-02-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/2/e003625.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/10/2/e003625.full

Similar Items